Vaccine to Prevent Hereditary Cancers Nears Human Trials

Exciting update! According to an article published by the National Cancer Institute Division of Cancer Prevention, “first-ever vaccines for the prevention of colorectal and other cancers in patients at high genetic risk for these malignancies is expected to start its early phase safety and immunogenicity trial in the first quarter of 2022”.

Although still in the design phase, the study will test a neoantigen-based vaccine against Lynch syndrome, a common hereditary condition that carries a 70-80% lifetime risk for colorectal cancer. The syndrome also raises the risk for developing endometrial cancer and several other cancers, often before age 50 years.

Learn More:
https://prevention.cancer.gov/news-and-events/blog/vaccine-prevent-hereditary#.YPnThQHKzHE.facebook

Vaccine to Prevent Hereditary Cancers Nears Human Trials was originally published by the National Cancer Institute." For questions, contact CancerPreventionBlog@mail.nih.gov.